30 Oct 2007 - Biota Holdings announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties for Relenza were AU$4.5m during the three months ended 30 September 2007. GSK reported sales of Relenza of 28m, down 7% on the comparable quarter last year.
Biota CEO, Peter Cook commented, "The Q1 figures are consistent with Biota's expectation that GSK will sell its installed capacity over the year. These are the summer quarter sales in the northern hemisphere and are typically the lowest of the yearâ"
Biota also confirmed that from this quarter, it will retain the full royalty and is no longer obliged to pass on any payment to third parties.
 |
www.bionity.com/news/e/72569 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/72569 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |